TickerFacts.

OnKure Therapeutics, Inc. (OKUR): Cash & Equivalents

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2023-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$59.05M
As of 2025-12-31
$166.50M
As of 2026-06-30
$124.66M2020-12-31: $53.61M2021-12-31: $124.66M2022-12-31: $19.93M2023-12-31: $29.88M2024-12-31: $110.76M2025-12-31: $59.05M$59.05M
2020-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$59.05M-46.7%2026-03-12, Balance as of period end
2024-12-31$110.76M+270.7%2026-03-12, Balance as of period end
2023-12-31$29.88Mn/c2025-03-10, Balance as of period end
2022-12-31$19.93M-84.0%2024-03-28, Balance as of period end
2021-12-31$124.66M+132.5%2023-03-27, Balance as of period end
2020-12-31$53.61Mn/a2022-03-23, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
OnKure Therapeutics, Inc. (OKUR)2025-12-31$59.05M-46.7%
Lifevantage Corp (LFVN)2025-06-30$20.20M+19.6%
Rallybio Corp (RLYB)2025-12-31$31.37M+125.7%
AN2 Therapeutics, Inc. (ANTX)2025-12-31$19.94M-6.6%
Q32 Bio Inc. (QTTB)2025-12-31$48.30M-38.1%
DiaMedica Therapeutics Inc. (DMAC)2025-12-31$15.65M+417.3%
Pasithea Therapeutics Corp. (KTTA)2025-12-31$55.16M+696.8%
ProPhase Labs, Inc. (PRPH)2025-12-31$90.0K-86.7%
Palvella Therapeutics, Inc. (PVLA)2025-12-31$57.98M-30.6%

Compare OKUR, LFVN, RLYB, ANTX side by side · Screen every company in Pharmaceutical Preparations ↗